CAR T-Cell Therapy Market Size To Reach 27.5 Billion by 2033 Owing to Rising Awareness and Favourable Reimbursement Policies Says Astute Analytica [Yahoo! Finance]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Yahoo! Finance
billion by 2033, reflecting a robust CAGR of 26.2%. The surge in demand is fueled by the success of FDA-approved CAR T-cell products such as Yescarta and Kymriah, which have demonstrated strong market performance. In 2023, Yescarta generated USD 1.4 billion in sales, with over 1,300 patients treated, while Kymriah achieved USD 443 million in sales in 2024, driven by its effectiveness in paediatric acute lymphoblastic leukemia (pALL) and follicular lymphoma (FL) outside the United States . More recently, Carvykti recorded net sales of USD 500 million within its first year of launch, underscoring the increasing demand for CAR T-cell therapies. Download Sample Copy: https://www.astuteanalytica.com/request-sample/car-t-cell-therapy-market The therapy
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)PR Newswire
- Novartis AG (VTX:NOVN) most popular amongst individual investors who own 53% of the shares, institutions hold 42% [Yahoo! Finance]Yahoo! Finance
- Isomorphic Labs announces $600 million funding to further develop its next-generation AI drug design engine and advance therapeutic programs into the clinic [Yahoo! Finance]Yahoo! Finance
- Here's Why Novartis (NVS) is a Strong Value Stock [Yahoo! Finance]Yahoo! Finance
- FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer [Yahoo! Finance]Yahoo! Finance
NVS
Earnings
- 1/31/25 - Beat
NVS
Sec Filings
- 4/3/25 - Form 6-K
- 3/28/25 - Form 6-K
- 1/31/25 - Form 6-K
- NVS's page on the SEC website